A 12-months Phase 2b trial of PrimeC from Israel’s NeuroSense (see here previously) showed a 73% improvement over placebo in slowing ALS progression among patients. It also achieved a 63% increase in survival rates. https://finance.yahoo.com/news/neurosenses-paradigm-als-clinical-trial-132700722.html  

Israel’s NeuraLight (see here) and NeuroSense Therapeutics (see here) are partnering to improve the diagnosis and monitoring of Amyotrophic lateral sclerosis (ALS). They will study patients using NeuroSense’s biological markers, together with Neuralight’s digital oculometric biomarkers. https://www.calcalistech.com/ctechnews/article/rj06yaktc

The US FDA has given Orphan drug status to the PrimeC ALS therapy from Israel’s NeuroSense (see here). Meanwhile, NeuroSense has begun Phase 1 human clinical trials of PrimeC at two US sites and a Phase 2a human trial at … Continue reading →

Israel’s NeuroSense Therapeutics is developing a treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. It is based on a discovery by Weizmann Institute Professor Eran Hornstein of a micro-RNA molecule lacking in the muscles of ALS … Continue reading →